Preclinical models: Needed in translation? A Pro/Con debate

Movement Disorders

Volumn 29, Issue 11, 2014, Pages 1391-1396

  Philips, Thomas ^a   Rothstein, Jeffrey D ^a   Pouladi, Mahmoud A ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Animal models; HTT; Huntington's; Transgenic; Translation

Indexed keywords

ANIMAL; DISEASE MODEL; GENETICS; HUMAN; HUNTINGTON CHOREA; PRECLINICAL STUDY; PROCEDURES; TRANSLATIONAL RESEARCH;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; HUNTINGTON DISEASE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84907926731     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26010     Document Type: Article

References (41)

1. Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci 2013;14:708-721.
2. Faber PW, Alter JR, MacDonald ME, Hart AC. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci USA 1999;96:179-84.
3. O'Sullivan GJ, O'Tuathaigh CM, Clifford JJ, O'Meara GF, Croke DT, Waddington JL. Potential and limitations of genetic manipulation in animals. Drug Discov Today Technol 2006;3:173-180.
4. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87:493-506.
5. Jackson GR, Salecker I, Dong X, et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998;21:633-642.
6. Romero E, Cha G-H, Verstreken P, et al. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron 2008;57:27-40.
7. Li Y, Ray P, Rao EJ, et al. A Drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci U S A 2010;107:3169-3174.
8. Tieu K. A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med 2011;1:a009316.
9. Yu-Taeger L, Petrasch-Parwez E, Osmand AP, et al. A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease. J Neurosci 2012;32:15426-15438.
10. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986;321:168-171.
11. Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AW. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 2008;453:921-924.
12. Jacobsen JC, Bawden CS, Rudiger SR, et al. An ovine transgenic Huntington's disease model. Hum Mol Genet 2010;19:1873-1882.
13. Yang D, Wang C-E, Zhao B, et al. Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Hum Mol Genet 2010;19:3983-3994.
14. Delli Carri A, Onorati M, Castiglioni V, et al. Human pluripotent stem cell differentiation into authentic striatal projection neurons. Stem Cell Rev 2013;9:461-474.
15. Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009;187:761-772.
16. Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 2002;125:1908-1922.
17. Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012;74:1031-1044.
18. Clabough EBD. Huntington's disease: the past, present, and future search for disease modifiers. Yale J Biol Med 2013;86:217.
19. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011;10:83-98.
20. Gil-Mohapel JM. Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice. CNS Neurosci Ther 2012;18:77-86.
21. Gil JM, Rego AC. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Brain Res Rev 2009;59:410-431.
22. Katsuno M, Tanaka F, Sobue G. Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2012;83:329-335.
23. Myers RH. Huntington's disease genetics. NeuroRx 2004;1:255-262.
24. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372.
25. Hayden MR, Leavitt BR, Yasothan U, Kirkpatrick P. Tetrabenazine. Nature Rev Drug Discovery 2009; 17-18.
26. Wang H, Chen X, Li Y, Tang T-S, Bezprozvanny I. Tetrabenazine is neuroprotective in Huntington's disease mice. Mol Neurodegener 2010;5:18.
27. Hanahan D, Wagner EF, Palmiter RD. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev 2007;21:2258-2270.
28. Nagy A. Cre recombinase: the universal reagent for genome tailoring. Genesis 2000;26:99-109.
29. Wang N, Gray M, Lu X-H, et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Nat Med 2014;20:536-541.
30. Hult S, Soylu R, Björklund T, et al. Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metab 2011;13:428-439.
31. Crotti A, Benner C, Kerman BE, et al. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci 2014;17:513-521.
32. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676.
33. Kim H, Kim J-S. A guide to genome engineering with programmable nucleases. Nat Rev Genet 2014;15:321-334.
34. HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 2012;11:264-278.
35. An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, et al. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012;11:253-263.
36. Kaye JA, Finkbeiner S. Modeling Huntington's disease with induced pluripotent stem cells. Mol Cell Neurosci 2013;56:50-64.
37. Ross CA, Akimov SS. Human-induced pluripotent stem cells: potential for neurodegenerative diseases. Hum Mol Genet 2014;May 13.
38. Carri AD, Onorati M, Lelos MJ, et al. Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development 2013;140:301-312.
39. Gu X, Li C, Wei W, et al. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005;46:433-444.
40. Gu X, André VM, Cepeda C, et al. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegen 2007;2:8.
41. Tong X, Ao Y, Faas GC, et al. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nat Neurosci 2014;17:694-703.